Top

Published in:

01-06-2015 | Research Article

Elevated expression of HABP1 is a novel prognostic indicator in triple-negative breast cancers

Authors: Ji Wang, Yanni Song, Tong Liu, Qingyu Shi, Zhenbin Zhong, Wei Wei, Suyun Huang, Da Pang

Published in: Tumor Biology | Issue 6/2015

Abstract

Hyaluronan-binding protein 1 (HABP1) has been documented to overexpress in several malignancies. The aim of our study is to investigate the expression of HABP1 protein in triple-negative breast cancer (TNBC) and its clinical significance. Using immunohistochemistry, HABP1 expression was evaluated in 139 TNBC specimens. The association between HABP1 expression with clinicopathological parameters was assessed using chi-square test. The survival status of patients was analyzed using the Kaplan–Meier and log-rank tests. Cox regression was used for the multivariate analysis of prognostic factors. The results showed that HABP1 overexpression correlated with higher histological grade (P = 0.004), advanced TNM stage (P = 0.008), greater tumor size (P = 0.016), metastasis of lymph node (P < 0.001), and recurrence (P = 0.040). Furthermore, it indicated that patients with HABP1 overexpression had significantly poorer overall survival (OS) and disease-free survival (DFS) compared with patients (P < 0.001 for both). Multivariate Cox regression analysis revealed that elevated HABP1 expression was an independent prognostic factor for both OS (P = 0.035) and DFS (P = 0.013). In contrast to the effect of HABP1 in TNBCs with lymph node metastasis, HABP1 overexpression significantly affects prognosis (OS, P = 0.002; DFS, P = 0.003) in TNBCs without lymph node metastasis. In conclusion, HABP1 protein high expression may contribute to the tumor progression and poor prognosis of TNBC, especially in predicting prognosis in TNBCs without lymph node metastasis.

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, PR-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109(9):1721–8.CrossRefPubMed

Kilburn LS. TNT Trial Management Group. ‘Triple negative’ breast cancer: a new area for phase III breast cancer clinical trials. Clin Oncol R Coll Radiol. 2008;20(1):35–9.CrossRefPubMed

Reis-Filho JS, Tutt AN. Triple negative tumors: a critical review. Histopathology. 2008;52(1):108–18.CrossRefPubMed

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95.CrossRefPubMedPubMedCentral

Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;118(22):5463–72.CrossRefPubMedPubMedCentral

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–34.CrossRefPubMed

Gupta S, Datta K. Possible role of hyaluronectin on cell adhesion in rat histiocytoma. Exp Cell Res. 1991;195(2):386–94.CrossRefPubMed

Deb TB, Datta K. Molecular cloning of human fibroblast hyaluronic acid-binding protein confirms its identity with P-32, a protein co-purified with splicing factor SF2. Hyaluronic acid-binding protein as P-32 protein, co-purified with splicing factor SF2. J Biol Chem. 1996;271(4):2206–12.CrossRefPubMed

Majumdar M, Datta K. Assignment of cDNA encoding hyaluronic acid-binding protein 1 to human chromosome 17p12-p13. Genomics. 1998;51(3):476–7.CrossRefPubMed

10.

Krainer AR, Mayeda A, Kozak D, Binns G. Functional expression of cloned human splicing factor SF2: homology to RNA-binding proteins, U1 70 K, and Drosophila splicing regulators. Cell. 1991;66(2):383–94.CrossRefPubMed

11.

Ranganathan S, Ganguly AK, Datta K. Evidence for presence of hyaluronan binding protein on spermatozoa and its possible involvement in sperm function. Mol Reprod Dev. 1994;38(1):69–76.CrossRefPubMed

12.

Das S, Deb TB, Kumar R, Datta K. Multifunctional activities of human fibroblast 34-kDa hyaluronic acid-binding protein. Gene. 1997;190(1):223–5.CrossRefPubMed

13.

Rao CM, Deb TB, Datta K. Hyaluronic acid induced hyaluronic acid binding protein phosphorylation and inositol triphosphate formation in lymphocytes. Biochem Mol Biol Int. 1996;40(2):327–37.PubMed

14.

Rao CM, Deb TB, Gupta S, Datta K. Regulation of cellular phosphorylation of hyaluronan binding protein and its role in the formation of second messenger. Biochim Biophys Acta. 1997;1336(3):387–93.CrossRefPubMed

15.

Itahana K, Zhang Y. Mitochondrial p32 is a critical mediator of ARF-induced apoptosis. Cancer Cell. 2008;13(6):542–53.CrossRefPubMedPubMedCentral

16.

Reef S, Shifman O, Oren M, Kimchi A. The autophagic inducer smARF interacts with and is stabilized by the mitochondrial p32 protein. Oncogene. 2007;26(46):6677–83.CrossRefPubMed

17.

Xin T, Zhang F, Jiang Q, Chen C, Huang D, Li Y, et al. Extraction, purification and antitumor activity of a water-soluble polysaccharide from the roots of Polygala tenuifolia. Carbohydr Polym. 2012;90(2):1127–31.CrossRefPubMed

18.

Rubinstein DB, Stortchevoi A, Boosalis M, Ashfaq R, Ghebrehiwet B, Peerschke EI, et al. Receptor for the globular heads of C1q (gC1q-R, p33, hyaluronan-binding protein) is preferentially expressed by adenocarcinoma cells. Int J Cancer. 2004;110(5):741–50.CrossRefPubMed

19.

Ghosh I, Chowdhury AR, Rajeswari MR, Datta K. Differential expression of hyaluronic acid binding protein 1 (HABP1)/P32/C1QBP during progression of epidermal carcinoma. Mol Cell Biochem. 2004;267(1–2):133–9.CrossRefPubMed

20.

Chen YB, Jiang CT, Zhang GQ, Wang JS, Pang D. Increased expression of hyaluronic acid binding protein 1 is correlated with poor prognosis in patients with breast cancer. J Surg Oncol. 2009;100(5):382–6.CrossRefPubMed

21.

Prakash M, Kale S, Ghosh I, Kundu GC, Datta K. Hyaluronan-binding protein 1 (HABP1/p32/gC1qR) induces melanoma cell migration and tumor growth by NF-kappa B dependent MMP-2 activation through integrin α(v)β(3) interaction. Cell Signal. 2011;23(10):1563–77.CrossRefPubMed

22.

Yu H, Liu Q, Xin T, Xing L, Dong G, Jiang Q, et al. Elevated expression of hyaluronic acid binding protein 1 (HABP1)/P32/C1QBP is a novel indicator for lymph node and peritoneal metastasis of epithelial ovarian cancer patients. Tumour Biol. 2013;34(6):3981–7.CrossRefPubMed

23.

Zhao J, Liu T, Yu G, Wang J. Overexpression of HABP1 correlated with clinicopathological characteristics and unfavorable prognosis in endometrial cancer. Tumour Biol. 2014 Oct;30.

24.

Alizadeh AA, Ross DT, Perou CM, van de Rijn M. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol. 2001;195(1):41–52.CrossRefPubMed

25.

Singletary SE, Greene FL. Revision of breast cancer staging: the 6th edition of the TNM classification. Semin Surg Oncol. 2003;21:53–9.CrossRefPubMed

26.

Kaul R, Saha P, Saradhi M, Prasad RL, Chatterjee S, Ghosh I, et al. Overexpression of hyaluronan-binding protein 1 (HABP1/p32/gC1qR) in HepG2 cells leads to increased hyaluronan synthesis and cell proliferation by up-regulation of cyclin D1 in AKT-dependent pathway. J Biol Chem. 2012;287(23):19750–64.CrossRefPubMedPubMedCentral

27.

Zhang X, Zhang F, Guo L, Wang Y, Zhang P, Wang R, et al. Interactome analysis reveals that C1QBP (complement component 1, q subcomponent binding protein) is associated with cancer cell chemotaxis and metastasis. Mol Cell Proteomics. 2013;12(11):3199–209.CrossRefPubMedPubMedCentral

28.

Yu G, Wang J. Significance of hyaluronan binding protein (HABP1/P32/gC1qR) expression in advanced serous ovarian cancer patients. Exp Mol Pathol. 2013;94(1):210–5.CrossRefPubMed

29.

Bialucha CU, Ferber EC, Pichaud F, Peak-Chew SY, Fujita Y. p32 is a novel mammalian Lgl binding protein that enhances the activity of protein kinase Czeta and regulates cell polarity. J Cell Biol. 2007;178(4):575–81.CrossRefPubMedPubMedCentral

30.

von Maltzahn G, Ren Y, Park JH, Min DH, Kotamraju VR, Jayakumar J, et al. In vivo tumor cell targeting with “click” nanoparticles. Bioconjug Chem. 2008;19(8):1570–8.CrossRef

31.

Saha P, Ghosh I, Datta K. Increased hyaluronan levels in HABP1/p32/gC1qR overexpressing HepG2 cells inhibit autophagic vacuolation regulating tumor potency. PLoS One. 2014;9(7):e103208.CrossRefPubMedPubMedCentral

32.

Meenakshi J. Anupama, Goswami SK, Datta K. Constitutive expression of hyaluronan binding protein 1 (HABP1/p32/gC1qR) in normal fibroblast cells perturbs its growth characteristics and induces apoptosis. Biochem Biophys Res Commun. 2003;300(3):686–93.CrossRefPubMed

33.

Kamal A, Datta K. Upregulation of hyaluronan binding protein 1 (HABP1/p32/gC1qR) is associated with cisplatin induced apoptosis. Apoptosis. 2006;11(5):861–74.CrossRefPubMed

Title: Elevated expression of HABP1 is a novel prognostic indicator in triple-negative breast cancers
Authors: Ji Wang
Yanni Song
Tong Liu
Qingyu Shi
Zhenbin Zhong
Wei Wei
Suyun Huang
Da Pang
Publication date: 01-06-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3131-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2015

SOX11 expression in chronic lymphocytic leukemia correlates with adverse prognostic markers

Epigenetic inactivation of SOX1 promotes cell migration in lung cancer

Genetic analysis and preliminary function study of miR-423 in breast cancer

Clinical significance of Sam68 expression in endometrial carcinoma

Prognostic value of soluble H7-B4 in pleural effusion associated with lung cancer

TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer